The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy

• DOI: 10.1007/s13277-015-3503-2
• Publication Date: 2015-04-30T12:09:16Z
• Authors: Ying-En Lee; Hong-Lin He; Yow-Ling Shiue; Sung-Wei Lee; Li-Ching Lin; Ting-Feng Wu; I-Wei Chang; Hao-Hsien Lee; Chien-Feng Li
• Keywords: Chemoradiotherapy

Neoadjuvant concurrent chemoradiotherapy has been widely used for rectal cancer to improve local tumor control. The varied response of individual tumors encouraged us search useful biomarkers predict the therapeutic response. study was aimed evaluate prognostic impact lipid biosynthesis-associated in patients treated with preoperative chemoradiotherapy. Through analysis previously published gene expression profiling database focusing on genes associated biosynthesis, we found that HSD17B2 and HMGCS2 were top two significantly upregulated non-responders. We further evaluated their by immunohistochemistry pre-treatment specimens from 172 statistically analyzed associations between various clinicopathological factors, as well survival. High or advanced pre- post-treatment nodal status (P < 0.001) lower regression grade 0.001). More importantly, high either significance, overexpression indicating poor prognosis disease-free survival = 0.0003), recurrence-free 0.0115), metastasis-free 0.0119), while <0.0001), 0.0009), 0.0001). In multivariate analysis, only remained an independent prognosticator shorter 0.008). conclusion, predicted susceptibility Both acted promising particularly HSD17B2.